OMERS ADMINISTRATION Corp Takes $1.01 Million Position in BioNTech SE (NASDAQ:BNTX)

OMERS ADMINISTRATION Corp purchased a new stake in BioNTech SE (NASDAQ:BNTX) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 8,900 shares of the company’s stock, valued at approximately $1,014,000.

A number of other large investors also recently made changes to their positions in the stock. SG Americas Securities LLC increased its position in shares of BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after buying an additional 33,375 shares in the last quarter. Mirabaud & Cie SA bought a new stake in shares of BioNTech in the 4th quarter valued at $684,000. Bank of New York Mellon Corp increased its position in shares of BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after buying an additional 150 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of BioNTech in the 4th quarter valued at $1,118,000. Finally, Van ECK Associates Corp increased its position in shares of BioNTech by 25.1% in the 4th quarter. Van ECK Associates Corp now owns 118,418 shares of the company’s stock valued at $13,493,000 after buying an additional 23,733 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $134.00 price objective (down previously from $145.00) on shares of BioNTech in a research report on Wednesday. Morgan Stanley lowered their price objective on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. Citigroup restated a “buy” rating and issued a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. BMO Capital Markets increased their target price on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $142.08.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $92.77 on Friday. The stock has a market capitalization of $22.30 billion, a price-to-earnings ratio of -44.18 and a beta of 1.35. The business has a 50-day moving average of $97.41 and a 200-day moving average of $108.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.90 EPS. As a group, sell-side analysts predict that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.